Home / Business and Economy / City Therapeutics Eyes $956M Valuation in IPO

City Therapeutics Eyes $956M Valuation in IPO

9 Oct

Summary

City Therapeutics announced an IPO targeting up to $956.3 million.
The company is proceeding with its listing despite market uncertainty.
The IPO aims to raise significant capital for the biotech firm.

City Therapeutics has announced its intention to pursue an initial public offering (IPO) in the United States. The biotech firm is aiming for a significant valuation, targeting an amount of up to $956.3 million. This public offering is proceeding amid a backdrop of market uncertainty.

Despite the challenging economic climate, City Therapeutics is moving forward with its listing plans. This decision highlights a continued interest in biotech sector investments. The company's IPO is poised to raise considerable capital, reflecting potential growth and development within the firm.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.